



TYPE	ITEM No.	INDICATION	REASON	CONDITIONS FOR ELIGIBILITY
<b>ONCOLOGY</b>				
Lung	61523	Solitary Pulmonary Nodule	Evaluation	MUST BE unsuitable for biopsy OR pathological characterisation has failed
	61529	Proven non small cell lung cancer	Primary Staging	Where curative surgery OR radiotherapy is planned
Brain	61535	Suspected primary brain tumour	Evaluation	To guide surgical biopsy AND to assist in treatment planning
	61538	Residual structural lesion & symptoms	Evaluation	Based on anatomical imaging findings AFTER definitive therapy for Glioma
Colorectal	61541	Residual Structural Lesion	Evaluation	For a SYMPTOMATIC patient AFTER definitive therapy for colorectal carcinoma
	61547	Isolated liver or pulmonary metastasis	Pre-operative evaluation	FOLLOWING previous therapy for colorectal carcinoma AND where surgical resection is planned
Malignant Melanoma	61553	Limited metastatic disease	Pre-operative evaluation	WHERE surgical resection is planned
Ovarian	61565	Epithelial OV Ca with suspected tumour recurrence	Evaluation	FOLLOWING initial therapy and where there are equivocal anatomical imaging findings or elevation of CA-125
Uterine Cervix	61571	Proven Ca of uterine cervix	Primary Staging	PRIOR to planned radical radiation therapy OR combined modality therapy
Oesophageal	61577	Proven Ca	Staging	WHERE curative surgery or chemoradiation is planned
Gastric	61583	Proven Ca	Staging	WHERE curative surgery is planned
Head & Neck	61595	Ca of Head & Neck	Primary Staging	FDG PET study (Head & Neck)
	61598	Ca of Head & Neck	"	Whole body FDG PET study (Head & Neck)
	61601	Ca of Head & Neck	Evaluation	For further investigation of suspected RESIDUAL or RECURRENT DISEASE
	61604	"	"	For further investigation of suspected RESIDUAL or RECURRENT DISEASE (Whole Body)
Ca of Unknown Origin	61607	Metastatic squamous cell Ca	Evaluation	Squamous cell Ca involving cervical nodes from an unknown primary site
	61610	"	"	Squamous cell Ca involving cervical nodes from an unknown primary site
Lymphoma Hodgkin's or Non-Hodgkin's	61616	Newly diagnosed	Staging	Newly diagnosed or previously untreated Hodgkin's or Non-Hodgkin's Lymphoma
	61622	Residual mass	Evaluation	After treatment for Lymphoma
	61628	Suspected recurrence/residual disease	Re-Staging	After treatment for Lymphoma
Sarcoma	61634	Suspected bone or soft tissue sarcoma	Guidance for biopsy	Structural imaging suggests lesional heterogeneity
	61640	Biopsy proven bone or soft tissue sarcoma	Staging or Re-staging	MUST BE considered suitable for resection of primary or limited metastatic disease if appropriate
	61646	Residual or recurrent sarcoma	Evaluation	Suspected disease on the basis of structural imaging after therapy
Follow-up of Ca	61589	Ca shown to be +ve on previous FDG PET scan	Follow-up	FDG PET study if 1. The previous scan was eligible for Medicare benefit because of HEALTH INSURANCE DETERMINATION HS/3/1997 2. The scan is not eligible for Medicare benefit otherwise than because of HEALTH INSURANCE DETERMINATION HS/02/2001 AND 3. The scan is required to assess response to treatment or possible tumour recurrence
<b>NEUROLOGY</b>				
Neurologic	61559	Refractory epilepsy	Evaluation	FDG PET study: Where surgery is being considered AND standard assessments are inconclusive for localisation
<b>CARDIOLOGY</b>				
Cardiac	61562	Ischaemic heart disease	Evaluation	FDG PET study: Where surgery is being considered for impaired left ventricular function AND standard myocardial viability tests are negative or equivocal for ischaemia